EvoGradient evolves antimicrobial peptides active against resistant pathogens
EvoGradient uses an explainable deep-learning potency model and virtual sequence evolution to optimize candidate antimicrobial peptides. Applied to peptides encoded by low-abundance human oral bacteria, it virtually evolved 32 candidates; the six most effective were synthesized and tested against multidrug-resistant pathogens. The authors report activity across carbapenem-resistant E. coli, K. pneumoniae and A. baumannii and vancomycin-resistant E. faecium; pep-19-mod reduced bacterial loads by more than 95% in mouse thigh-infection models under the reported systemic and local administrations. These are preclinical findings and do not establish human efficacy or safety.
Technology: Explainable deep-learning antimicrobial-peptide potency model with gradient-based virtual sequence evolution
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Six synthesized peptides were tested against multidrug-resistant pathogens; the authors also report pep-19-mod in-vivo testing in mouse thigh-infection models, with over 95% bacterial-load reduction under the described systemic and local administration.
- Still unknown: Mouse infection outcomes do not establish human safety, dosing, efficacy or clinical translation; only six candidates from the 32 virtual evolutions were synthesized and tested.
- AI role: EvoGradient predicts peptide potency and virtually modifies peptide sequences through gradient-based evolution; the workflow selected optimized candidates for synthesis and experimental testing.
Evidence sources: https://www.nature.com/articles/s41564-024-01907-3 · https://pubmed.ncbi.nlm.nih.gov/39825096/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Nature Microbiology indexed article text and primary PubMed abstract/metadata/affiliations; conclusions limited to reported preclinical assays..
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.